Topic Hub
6 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 6 of 6 clinical reviews.
Evidence review of bremelanotide (Vyleesi) efficacy differences in Hispanic / Latino populations, covering RECONNECT trial subgroup data, MC4R pharmacogenomics, metabolic confounders, and practical dosing guidance.
Read clinical reviewEvidence-based review of bremelanotide (Vyleesi) efficacy in South Asian women, including MC4R pharmacogenomics, cardiovascular screening at lower BMI thresholds, and ethnicity-stratified trial gaps.
Read clinical reviewEvidence-based review of how bremelanotide (Vyleesi) safety, pharmacogenomics, and dosing considerations differ for South Asian women, including cardiovascular monitoring and melanocortin receptor variability.
Read clinical reviewA clinical deep-dive into bremelanotide (Vyleesi) safety and efficacy differences in East Asian women, covering CYP2C19/CYP2D6 pharmacogenomics, BMI-adjusted dosing considerations, and what the RECONNECT trial data reveal about ethnicity-stratified outcomes.
Read clinical reviewA clinician-reviewed deep dive into bremelanotide (Vyleesi) pharmacogenomics, dosing, and safety considerations specific to Hispanic and Latino women, with ethnicity-stratified data, CYP variant analysis, and RECONNECT trial subgroup findings.
Read clinical reviewA clinical review of bremelanotide (Vyleesi) pharmacokinetics, pharmacogenomics, and cardiovascular considerations specific to South Asian patients, including practical dosing guidance reviewed by HealthRX.com physicians.
Read clinical review